Geriatrics
Conference Coverage
AHA: Broadening evidence for CABG over PCI in diabetics
Key clinical point: New evidence reinforces CABG as preferred over PCI for revascularization in diabetic patients with multivessel CAD. Major...
Conference Coverage
VIDEO: Monitoring helps only adherent heart failure patients
Key clinical point: Remote monitoring failed to reduce mortality or hospitalizations for all patients during the 180 days following heart failure...
Conference Coverage
AHA: Coronary calcium personalizes ACC/AHA risk calculator
Key clinical point: Measuring coronary artery calcium provides added value in refining the 10-year atherosclerotic cardiovascular disease risk,...
Conference Coverage
ACR: Infection risk with DMARDs doesn’t change with age of RA onset
Key clinical point: Patients with older onset RA can be safely treated with biologics. Major finding: There was no significant difference in...
Conference Coverage
AHA: PCI renal complications keep climbing
Renal complication rates in Medicare patients undergoing PCI continue to rise dramatically.
Conference Coverage
ACR: Don’t give pneumococcal vaccine to CAPS, Behçet’s patients
Pneumococcal vaccines can trigger severe local and systemic inflammatory reactions in patients with cryopyrin-associated periodic syndromes,...
Conference Coverage
VIDEO: SPRINT results rebut JNC 8’s blood pressure targets
Conference Coverage
VIDEO: U.S. hepatitis C treatment capacity falls short of need
Despite new hepatitis C treatment options, the health care system’s capacity to treat patients still falls far short of what’s needed.
Conference Coverage
Riociguat deemed suitable for PAH in connective tissue disease
Key clinical point: Patients with pulmonary arterial hypertension and connective tissue disease can benefit from riociguat treatment. Major...
Conference Coverage
AHA: Sacubitril/valsartan cuts heart failure hospital readmissions
Key clinical point: In the PARADIGM-HF pivotal trial, treating chronic heart failure with reduced ejection fraction with sacubitril/valsartan cut...
Conference Coverage
CTAD: New aducanumab subanalysis bolsters phase III trials in very mild Alzheimer’s
Key clinical point: A subanalysis of patients with very mild Alzheimer’s who received aducanumab in the PRIME trial provides some assurance that...